DIFFERENTIAL DEVELOPMENT OF TOLERANCE TO THE DEPRESSANT EFFECTS OF BENZODIAZEPINE AND NONBENZODIAZEPINE AGONISTS AT THE OMEGA (BZ) MODULATORY SITES OF GABA(A) RECEPTORS

被引:51
作者
SANGER, DJ
ZIVKOVIC, B
机构
[1] Synthelabo Recherche (L.E.R.S), 92220 Bagneux
关键词
TOLERANCE; BENZODIAZEPINES; ZOLPIDEM; ZOPICLONE; CL-218,872;
D O I
10.1016/0028-3908(92)90148-I
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In a previous study, it was found that both the benzodiazepine hypnotic, midazolam, and the imidazopyridine hypnotic, zolpidem, which has selective affinity for a sub-population of omega (benzodiazepine, BZ) modulatory sites of GABA, receptors, produced similar decreases in rates of food-reinforced lever pressing in rats. However, during 10 days of repeated administration, marked tolerance developed to the depressant effect of midazolam but little tolerance developed with zolpidem. It was found in the present study that, with a within-subject design similar to that used previously, tolerance developed to the response rate-decreasing activity of the benzodiazepine, triazolam and the cyclopyrrolone, zopiclone but not to that of the triazolopyridazine, CL 218,872. In another experiment, using a between-groups design, tolerance developed to the effect of midazolam, even if the injections were not associated with daily test sessions, providing no evidence for a drug-environment interaction. The lack of tolerance to zolpidem was confirmed in two experiments. There was little indication of tolerance to the depressant effect of zolpidem, even after 19 days administration of daily doses, up to 30 mg/kg, a dose 10 times greater than that which completely suppressed responding. These results showed that the extent to which tolerance develops to the effects of drugs with affinity for omega (BZ) modulatory sites can show wide variations which may be related to differences in mechanisms of action.
引用
收藏
页码:693 / 700
页数:8
相关论文
共 31 条
[11]   ANALYSIS OF THE ROLE OF BEHAVIORAL-FACTORS IN THE DEVELOPMENT OF TOLERANCE TO THE BENZODIAZEPINE MIDAZOLAM [J].
GRIFFITHS, JW ;
GOUDIE, AJ .
NEUROPHARMACOLOGY, 1987, 26 (2-3) :201-209
[12]  
GRIFFITHS JW, 1986, PSYCHOPHARMACOLOGY, V90, P513
[13]  
HERBERG LJ, 1987, PSYCHOPHARMACOLOGY, V93, P214
[14]   PHARMACOLOGICAL STUDIES ON ZOPICLONE [J].
JULOU, L ;
BARDONE, MC ;
BLANCHARD, JC ;
GARRET, C ;
STUTZMANN, JM .
PHARMACOLOGY, 1983, 27 :46-58
[15]   PHARMACOLOGICAL AND CLINICAL-STUDIES OF CYCLOPYRROLONES - ZOPICLONE AND SURICLONE [J].
JULOU, L ;
BLANCHARD, JC ;
DREYFUS, JF .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1985, 23 (04) :653-659
[16]  
KING DA, 1987, BEHAV NEUROSCI, V101, P104
[17]   LIMITATIONS OF THE BENZODIAZEPINE RECEPTOR NOMENCLATURE - A PROPOSAL FOR A PHARMACOLOGICAL CLASSIFICATION AS OMEGA RECEPTOR SUBTYPES [J].
LANGER, SZ ;
ARBILLA, S .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1988, 2 (03) :159-170
[18]  
LANGER SZ, 1988, IMIDAZOPYRIDINES SLE, P55
[19]   SYNTHETIC NON-BENZODIAZEPINE LIGAND FOR BENZODIAZEPINE RECEPTORS - PROBE FOR INVESTIGATING NEURONAL SUBSTRATES OF ANXIETY [J].
LIPPA, AS ;
COUPET, J ;
GREENBLATT, EN ;
KLEPNER, CA ;
BEER, B .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1979, 11 (01) :99-106
[20]  
MARGULES D L, 1968, Psychopharmacologia, V13, P74, DOI 10.1007/BF00401620